Affordable Access

Nasal vaccination using live bacterial vectors.

Authors
Type
Published Article
Journal
Advanced Drug Delivery Reviews
0169-409X
Publisher
Elsevier
Publication Date
Volume
51
Issue
1-3
Pages
55–69
Identifiers
PMID: 11516779
Source
Medline
License
Unknown

Abstract

Live recombinant bacteria represent an attractive means to induce both mucosal and systemic immune responses against heterologous antigens. Several models have now been developed and shown to be highly efficient following intranasal immunization. In this review, we describe the two main classes of live recombinant bacteria: generally recognized as safe bacteria and attenuated strains derived from pathogenic bacteria. Among the latter, we have differentiated the bacteria, which do not usually colonize the respiratory tract from those that are especially adapted to respiratory tissues. The strategies of expression of the heterologous antigens, the invasiveness and the immunogenicity of the recombinant bacteria are discussed.

Statistics

Seen <100 times